IRulya Therapeutics shared its third quarter 2026 results, showing $105.2 million in cash and investments.

Nov 13, 2026, 9:11 AM ETResultsRead the original at globenewswire.com

Good for IRLA

IRulya says $105.2 million should fund operations through the end of 2028, supporting continued work on LAM-001. The Phase 2 results are still pending, but the funding runway makes this update favorable.

IRLA · IRulya Therapeutics Inc.

AI read · Good for IRLA

The AI's read

That runway gives IRulya time to move LAM-001 toward two planned data readouts without reporting a need to raise more money. The main limit is that both readouts are still ahead, so this update does not show whether the drug works.

Get alerts for IRLA

Follow IRulya Therapeutics Inc. (IRLA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IRLA

Free on the App Store and Google Play, or on the web.